Abstract
We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.
Highlights
Advanced lung cancer (LC) is a leading cause of cancer deaths worldwide [1,2,3,4]
We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients
Baseline circulating levels of four types microparticles in study subjects The circulating levels of the PDAc-MPs, PDApMPs, EDAc-MPs and EDAp-MPs were significantly higher in advanced NSCLC patients compared to control subjects
Summary
Advanced lung cancer (LC) is a leading cause of cancer deaths worldwide [1,2,3,4]. Nearly 95% of all lung cancers are either small cell lung cancer (SCLC) or nonsmall cell lung cancer (NSCLC). Current treatments include a combination of traditional surgical interventions and adjunctive radiation and chemotherapy. Targeted drugs for LC include epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) like www.impactjournals.com/oncotarget gefitinib, erlotinib, and afatinib [5,6,7,8,9], and anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK TKI) like crizotinib [10]. Nearly 50% of lung cancer patients are diagnosed at an advanced stage [4]. Better understanding of the lung cancer pathogenesis and development of effective molecular and cellular biomarkers [4] are necessary to detect cancer early and improve therapeutic outcomes [15,16,17]. The development of serum biomarkers like microparticles would be useful to predict prognostic outcomes in LC [18,19,20,21]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
